Drugs / RESUGOSBART
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT04435158 | Aug 2020 → Jul 2022 | osteoporosis | Jiangsu HengRui Medicine Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT03870100 | Apr → Oct 2019 | osteoporosis | Jiangsu HengRui Medicine Co., Ltd. | Completed | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT03898024 | Apr 2019 → Jul 2020 | osteoporosis | Second Xiangya Hospital of Central South University | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RESUGOSBART | ChEMBL registry synonym — accepted as the source's own label CHEMBL5095382 ↗ |
| Known as | SHR-1222 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04435158 ↗ |
| Modality | Monoclonal antibody | — CHEMBL5095382 ↗ |
| Route | Subcutaneous | “Subjects received SHR-1222 at 50, 100, 200, 300, and 400 mg sequentially or matching placebo subcutaneously.” PMID 34744750 ↗ Oct 2021 |